A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Conditions
Metastatic Colorectal Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale University, New Haven, Connecticut, United States
START Midwest, Grand Rapids, Michigan, United States
Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland, Ohio, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Hämatologisch-Onkologische Praxis Eppendorf - HOPE, Hamburg, Germany
Asklepios Tumorzentrum Hamburg, Hamburg, Germany
National Cancer Center Hospital, Chūōku, Japan
National Cancer Center Hospital East, Kashiwa, Japan
Hospital HM Nou Delfos, Barcelona, Spain
Vall D'Hebrón Hospital, Barcelona, Spain
Centro Integral Oncologico Clara Campal, Madrid, Spain
Guy's & St Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom
Christie NHS Foundation, Manchester, United Kingdom
The Royal Marsden NHS, Sutton, United Kingdom
Study leads
BioNTech Responsible Person
Study Director
BioNTech SE